What are PDE10A inhibitor drugs?

PDE10A inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting PDE10A (phosphodiesterase 10A)). 1 are currently marketed, with 3 more in clinical development.

What are the marketed PDE10A inhibitor drugs?

Marketed PDE10A inhibitor drugs include ODM-203 (Period 1).

PDE10A inhibitor

1 marketed 3 in Phase 3

This page covers all PDE10A inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PDE10A (phosphodiesterase 10A), PDE10A (Phosphodiesterase 10A), PDE10A.

Targets

PDE10A (phosphodiesterase 10A) · PDE10A (Phosphodiesterase 10A) · PDE10A

Marketed (1)

ODM-203 (Period 1) · Orion Corporation, Orion Pharma · Neurology
ODM-203 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.

Phase 3 pipeline (3)

LY2062430 · Eli Lilly and Company · Neurology/Psychiatry
LY2062430 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain.
DMB-3115 · Dong-A ST Co., Ltd. · Neurology/Psychiatry
DMB-3115 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.
E3810 · Eisai Co., Ltd. · Neurology/Psychiatry
E3810 is a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide signaling in the brain.